Masimo secures FDA approval for OIRD detection on wearable patient monitor

Masimo has received 510(k) clearance from the FDA for an OIRD detection feature integrated into the Radius VSM patient monitor. The newly cleared capability uses AI through the smartSET pulse oximetry sensor platform. Visual alarms in the OIRD feature alert clinicians to condition changes and escalate as a patient’s risk increases. Credit: Masimo. Speciality diagnostics solutions developer Masimo has received 510(k) clearance from the US Food and Drug Administration (FDA) for an opioid-induced respiratory depression (OIRD) detection feature integrated into the Radius VSM patient monitor. The newly cleared capability uses AI via the smartSET pulse oximetry sensor platform, which is…

Source: Medical Device Network